Current Pathogenesis and Treatment of Cutaneous Lupus Erythematosus

Cut Putri Hazlianda; Ika Diamanda

doi:10.47353/jsocmed.v2i12.107

Current Pathogenesis and Treatment of Cutaneous Lupus Erythematosus

Cut Putri Hazlianda
Department of Dermatology Venereology and Aestethic, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Ika Diamanda
Department of Dermatology Venereology and Aestethic, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Abstract

Lupus erythematosus (LE) is a chronic autoimmune illness with a broad range of clinical symptoms. These conditions can range from systemic lupus erythematosus (SLE), which affects different organ systems in the body, to cutaneous lupus erythematosus (CLE), which affects only the skin. The precise pathophysiology of CLE is unknown, although it appears to include a complicated interaction of genetic predisposition and environmental stimuli such as UV light, medications, trauma, and hormones. The emergence of the inflammatory infiltrate seen in CLE lesions has also been documented in several studies; this information is crucial for figuring out which specific inflammatory mediators are responsible for tissue damage. Currently prescribed medications for CLE often include antimalarials, systemic corticosteroids, immunosuppressants, and immunomodulators; cytotoxic drugs are only used in the most severe instances.

Similar Articles

Rizki amaliah Damanik, Andika Pradana, Pandiaman Pandia, Blood Eosinophil Count as a Predictor of Asthma Exacerbation , Journal of Society Medicine: Vol. 4 No. 2 (2025): February
Dia Tri Susanti, Gema Nazri Yanni, Johannes H. Saing, Erna Mutiara, Aridamuriany D. Lubis, Olga R. Siregar, Correlation of Fibrinogen Level with PELOD-2 Score As A Predictive Factor For Mortality in Pediatric Sepsis , Journal of Society Medicine: Vol. 2 No. 11 (2023): November
Natassya Sandra Tillasman, Putu Pradnyasanti Laksmi, Ratna Rayeni Natasha Roosseno, Agus Roy Rusly Hariantana Hamid, Literature Review for Iliaca, Scapula, and Fibula Free Flap as A Modality in Mandibular Ameloblastoma Reconstruction , Journal of Society Medicine: Vol. 3 No. 6 (2024): June
Elsha Sinulingga Elsha, Jelita Siregar, Taufik Sungkar, Differences in MPV (Mean Platelet Volume) / Lymphocytes Ratio In Chronic Hepatitis B with and without Cirrhosis Hepatic , Journal of Society Medicine: Vol. 3 No. 6 (2024): June
Robert Sihombing, Osmond Muftilov Pison, Management of Patients with Guillain Barre Syndrome Accompanied by Ventilator Associated Pneumonia , Journal of Society Medicine: Vol. 3 No. 5 (2024): May
Romi Ridwan, Ezra Oktaliansyah, Case Series of Guillain Barre Syndrome with Plasmaparesis in The ICU Bandung Hospital , Journal of Society Medicine: Vol. 3 No. 4 (2024): April
Grace Nikensari, Ali Nafiah Nasution, Abdullah Afif Siregar, Monocyte to High-Density Lipoprotein Ratio (MHR) as A Predictor of Major Cardiovascular Events in Acute Myocardial Infarction Patients with ST-Segment Elevation in Patients Undergoing Primary Percutaneous Coronary Intervention at Haji Adam Malik Central General Hospital , Journal of Society Medicine: Vol. 3 No. 5 (2024): May
Antonius Leonardo Purba, Refli Hasan, Abdul Halim Raynaldo, The TIMI Risk Index as a Predictor of Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention at Haji Adam Malik Hospital Medan , Journal of Society Medicine: Vol. 4 No. 3 (2025): March
Monica Tampubolon, Kiki M. Iqbal, R. A. Dwi Pujiastuti, Osmolarity Changes after Mannitol Administration in Cerebral Edema Patients , Journal of Society Medicine: Vol. 2 No. 7 (2023): July
Dear Mohtar, Erias Erlangga, Management of Dengue Fever and Morbidly Obese in Pregnancy after C-Section , Journal of Society Medicine: Vol. 2 No. 10 (2023): October

<< < 1 2 3 4 5 6 > >>

You may also start an advanced similarity search for this article.

PDF

Published at

31. December 2023
https://doi.org/10.47353/jsocmed.v2i12.107
Issue:

Vol. 2 No. 12 (2023): December
Section:

Articles
Keywords:

Lupus erythematosus Cutaneous lupus erythematosus Pathogenesis Treatment
References:

Guo LN, Nambudiri VE. Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis. Clin Rheumatol. 2021;40(2):491–9.

Rees F, Doherty M, Grainge M, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology 2017b;56(11):1945–61.

Little AJ, Vesely MD. Cutaneous lupus erythematosus: Current and future pathogenesis-directed therapies. Yale J Biol Med. 2020;93(1):81–95.

Chang AY, Ghazi E, Okawa J, Werth VP. Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol 2013;149(1):104–6.

Billi AC, Gharaee-Kermani M, Fullmer J, Tsoi LC, Hill BD, Gruszka D, et al. The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity. JCI Insight. 2019;4(8).

Scofield RH, Bruner GR, Namjou B, Kimberly RP, RamseyGoldman R, Petri M, et al. Klinefelter’s syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58:2511–7

Cooney CM, Bruner GR, Aberle T, Namjou-Khales B, Myers LK, Feo L, et al. 46,X,del(X)(q13) Turner’s syndrome women with systemic lupus erythematosus in a pedigree multiplex for SLE. Genes Immun. 2009;10:478–81

Wang J, Syrett CM, Kramer MC, Basu A, Atchison ML, Anguera MC. Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X. Proc Natl Acad Sci U S A. 2016;113:E2029–38.

Syrett CM, Paneru B, Sandoval-Heglund D, et al. Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases. JCI Insight. 2019;4

Souyris M, Cenac C, Azar P, et al. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3:Eaap8855.

E.S Robinson, V.P. Werth. The Role of Cytokines in the Pathogenesis of Cutaneous Lupus Erythematosus. Elsevier. 2015; p 1-7

Jiaxuan C, Shuzhen L, Wanxian P, Fengbiao G, et al,. Life Factors Acting on Systemic Lupus Erythematosus. Frontiers in Immunology. 2022:1-10.

Blaine C, Kailey M, Shreya T, Esther M. Alcohol as a friend or foe in autoimmune diseases: a role for gut mictobiome. Taylor & Francis Group. 2021; 13(1): 1-15.

Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–32.

Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K. Fitzpatrick’s Dermatology in General Medicine. Ninth. New York: McGraw Hill; 2019.

Marco Q, Guido M, Marco DA, Cinzia B, Vincenzo C. Viral Infections and Systemic Lupus Erythematosus: New Players in a Old Story. MDPI. 2021; 13: 1-29

Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–32.

Günther C. Nucleic acid immunity in the pathogenesis of cutaneous lupus erythematosus. Front Immunol. 2019;10(JULY):1–9.

Kathryn C, Eric FM. Systemic Lupus Erythematosus: A Clinical Update. Internal Medicine Journal. 2021;51:1219-1228

Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–32.

Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: Current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208–14.

Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1–8.

Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019 Feb 18;129(3):1359–71.

Zimmermann N, Wolf C, Schwenke R, Lüth A, Schmidt F, Engel K, et al. Assessment of Clinical Response to Janus Kinase Inhibition in Patients with Familial Chilblain Lupus and TREX1 Mutation. JAMA Dermatology. 2019;155(3):342–6.

Fornaro M, Coladonato L, Venerito V, Cacciapaglia F, Lopalco G, Iannone F. Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. Rheumatol (United Kingdom). 2020;59(5):1188.

You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: The experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–3.

Van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, et al. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, PlaceboControlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020;72(5):761–8.

Lu Q, Long H, Chow S, Hidayat S, Danarti R, Listiawan Y, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. 2021;123(8):102707.
Share:

Z

Hazlianda, C. P., & Diamanda, I. (2023). Current Pathogenesis and Treatment of Cutaneous Lupus Erythematosus. Journal of Society Medicine, 2(12), 392–402. https://doi.org/10.47353/jsocmed.v2i12.107